ATE449612T1 - Zusammensetzung zur impfung - Google Patents

Zusammensetzung zur impfung

Info

Publication number
ATE449612T1
ATE449612T1 AT03750381T AT03750381T ATE449612T1 AT E449612 T1 ATE449612 T1 AT E449612T1 AT 03750381 T AT03750381 T AT 03750381T AT 03750381 T AT03750381 T AT 03750381T AT E449612 T1 ATE449612 T1 AT E449612T1
Authority
AT
Austria
Prior art keywords
compositions
immunogen
methods
vaccination
occlusion vehicle
Prior art date
Application number
AT03750381T
Other languages
English (en)
Inventor
Nikolai Kikrby
Peter Samuelsen
Original Assignee
Nordic Vaccine Technology As
Coloplast As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK200201473A external-priority patent/DK200201473A/da
Application filed by Nordic Vaccine Technology As, Coloplast As filed Critical Nordic Vaccine Technology As
Application granted granted Critical
Publication of ATE449612T1 publication Critical patent/ATE449612T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03750381T 2002-10-02 2003-10-02 Zusammensetzung zur impfung ATE449612T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41510202P 2002-10-02 2002-10-02
DK200201473A DK200201473A (da) 2002-10-02 2002-10-02 Vaccinepræparater
PCT/DK2003/000654 WO2004030696A2 (en) 2002-10-02 2003-10-02 Composition for vaccination

Publications (1)

Publication Number Publication Date
ATE449612T1 true ATE449612T1 (de) 2009-12-15

Family

ID=32070988

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03750381T ATE449612T1 (de) 2002-10-02 2003-10-02 Zusammensetzung zur impfung

Country Status (9)

Country Link
EP (1) EP1545605B8 (de)
JP (1) JP2006503072A (de)
AT (1) ATE449612T1 (de)
AU (1) AU2003269839B2 (de)
CA (1) CA2500911A1 (de)
DE (1) DE60330257D1 (de)
DK (1) DK1545605T3 (de)
NZ (1) NZ539008A (de)
WO (1) WO2004030696A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635488B2 (en) 2001-03-13 2009-12-22 Dbv Technologies Patches and uses thereof
FR2822049B1 (fr) 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
US7887842B2 (en) * 2003-02-07 2011-02-15 Teikoku Pharma Usa, Inc. Methods of administering a dermatological agent to a subject
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
ES2433467T3 (es) 2005-01-20 2013-12-11 Isconova Ab Composición de vacuna que comprende una proteína de unión a fibronectina o un péptido de unión a fibronectina
BRPI0707556A2 (pt) * 2006-02-07 2011-05-10 Nippon Biolog Inc veÍculo para vacina
EP2116266A1 (de) * 2007-03-01 2009-11-11 Cosmed Pharmaceutical Co., Ltd. Perkutan resorbierbare zubereitung, verfahren zu ihrer herstellung und perkutanes resorptionsverfahren
EP2116256A1 (de) * 2007-03-01 2009-11-11 Cosmed Pharmaceutical Co., Ltd. Transdermales immunpräparat, verfahren zu seiner herstellung und transdermales immunisierungsverfahren damit
FR2921562B1 (fr) * 2007-10-01 2012-06-15 Dbv Tech Dispositif adhesif pour application cutanee
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
FR2924350B1 (fr) * 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
WO2009106085A1 (en) * 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
WO2010013350A1 (ja) 2008-08-01 2010-02-04 Ａｓｐｉｏｎ株式会社 Ｓ／ｏ型経皮免疫剤
CN107441483A (zh) * 2010-04-16 2017-12-08 Dbv技术公司 免疫接种的方法
JP5263349B2 (ja) * 2011-08-08 2013-08-14 生化学工業株式会社 生理活性分子含有架橋ヘパリンゲル組成物
DK2750683T4 (da) 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
KR102484824B1 (ko) * 2020-09-03 2023-01-05 주식회사 중앙백신연구소 동물용 미끼백신 및 이의 제조방법
KR102621024B1 (ko) * 2023-09-12 2024-01-05 (주)진코스텍 심미감 및 피부 흡수력이 개선된 하이드로겔 패치

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
US5306504A (en) * 1992-12-09 1994-04-26 Paper Manufactures Company Skin adhesive hydrogel, its preparation and uses
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US5993852A (en) 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
EP1061951B1 (de) * 1998-02-25 2003-08-27 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp-ribosylating-exotoxin induzierten immunantwort
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1031346B1 (de) * 1999-01-27 2002-05-02 Idea Ag Nichtinvasive Impfung durch die Haut
WO2000061184A2 (en) * 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
GB9920167D0 (en) * 1999-08-25 1999-10-27 Avery Dennison Corp Pressure sensitive adhesive compositions
JP2004525921A (ja) * 2001-03-19 2004-08-26 イオマイ コーポレイシヨン 経皮免疫用パッチ
DE60229118D1 (de) * 2001-04-04 2008-11-13 Nordic Vaccine Technology As Polynukleotide-bindende komplexe die sterolen und saponine enthalten

Also Published As

Publication number Publication date
WO2004030696A3 (en) 2004-05-06
DK1545605T3 (da) 2010-04-12
CA2500911A1 (en) 2004-04-15
EP1545605B1 (de) 2009-11-25
EP1545605A2 (de) 2005-06-29
EP1545605B8 (de) 2010-05-26
JP2006503072A (ja) 2006-01-26
WO2004030696A8 (en) 2004-06-10
NZ539008A (en) 2006-10-27
WO2004030696A2 (en) 2004-04-15
AU2003269839A1 (en) 2004-04-23
AU2003269839B2 (en) 2006-07-27
DE60330257D1 (de) 2010-01-07

Similar Documents

Publication Publication Date Title
DE60330257D1 (de) Zusammensetzung zur impfung
Castellan et al. Effect of dentin biomodification using naturally derived collagen cross‐linkers: one‐year bond strength study
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BR0316758A (pt) Vacinas baseadas em levedura como imunoterapia
NO971192L (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
BR0113286A (pt) Pirazóis substituìdos
ATE269113T1 (de) Sprühfähige wundversorgungszusammensetzung
FR2827605B1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
Ricci et al. Wettability of chlorhexidine treated non‐carious and caries‐affected dentine
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
DK1313462T3 (da) Anvendelse af asiatisk syre eller asiaticosid til behandling af cancer
Mews et al. Shear bond strength of orthodontic brackets to enamel after application of a caries infiltrant
WO2008057158A3 (en) Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
ATE402211T1 (de) Verfahren zur herstellung von farblosen, lagerstabilen biuretgruppenhaltigen polyisocyanaten
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
DE60125528D1 (de) Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
SE9903534D0 (sv) Vaccin
EP1262491A3 (de) Nicht-anaphylaktogene IgE Impfstoffe
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties